---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324202"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-07-29T21:06:38+00:00"
generated_at: "2026-07-29T21:08:14.553301+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology amends executive severance agreements for CEO, CCO, and COO

## Summary
- CEO Wilson: 12 months base salary (non-CIC) or 24 months base + 200% bonus (CIC), full equity acceleration.
- CCO Powl and COO Ford: 12 months base (non-CIC) or 18 months base + 150% bonus (CIC), full equity acceleration.
- All executives get COBRA premium continuation (12 months non-CIC, 18-24 months CIC) and option exercise extension to 12 months.
- Amendments effective July 24-27, 2026; other terms unchanged.

## SEC filing metadata
- accession: 0001193125-26-324202
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-07-29T21:06:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/0001193125-26-324202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526324202/d53075d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324202
- JSON: https://secwatch.observer/filing/0001193125-26-324202.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.